SEPTEMBER 2025 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA September 22 – Vorasidenib – LGG IDH1/2. The European Commission (EC) has approved the first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma (subtypes of low-grade glioma, [LGG]) with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged […]
Diatech Pharmacogenetics will attend the MEDICA Exhibition 2025
We are pleased to announce that we will be exhibiting at MEDICA again this year We look forward to see you in Düsseldorf, from 11 to 14 November. H01; Booth N.1B34 From 17 to 20 November 2025, MEDICA will once again gather international experts from the medical industry in Düsseldorf, Germany. With over 5,300 exhibitors […]